AIX Ventures
VC Fund
San Francisco, United States
AIX Ventures is an AI fund and seed stage venture capital firm partnering top AI startups and AI practitioners. The firm specializes in investing in early-stage companies, particularly in the Pre/Seed stages, to foster innovative AI-driven solutions.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $61M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries AIX Ventures invests in
Stages AIX Ventures invests in
Countries AIX Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Investment Focus
Industry
- Artificial Intelligence 28 (45%)
- Software 16 (26%)
- Biotechnology 11 (18%)
- Machine Learning 8 (13%)
- Information Technology 5 (8%)
Stage
- Seed 30 (48%)
- Series A 9 (15%)
- Pre-Seed 7 (11%)
- Series C 3 (5%)
- Venture - Series Unknown 2 (3%)
Country
- United States 37 (60%)
- Canada 2 (3%)
- Germany 2 (3%)
- Israel 1 (2%)
- Switzerland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anthony Goldbloom
Investing Partner
|
Investing Partner | Total investments: 27 | Find email | |
Bianca Caban
Principal
|
Principal | Total investments: 1 | Find email | |
Christopher Manning
General Partner
|
General Partner | Total investments: 0 | Find email | |
Fang Yuan
General Partner
|
General Partner | Total investments: 0 | Find email | |
Jason McBride
partner
|
partner | Total investments: 5 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Chromie Health is an AI-driven healthcare company focused on improving scheduling and workflow efficiency. It uses technology to help healthcare teams manage appointments and operations more smoothly. The company’s goal is to reduce scheduling challenges and save staff time. Overall, it aims to make healthcare coordination faster, smarter, and moreefficient. | $2M / Pre-Seed / May 14, 2026 | ||
| BranchLab makes healthcare advertising better so that people may find the best healthcare options. | $28.8M / Series A / May 13, 2026 | ||
| Illoca is building a platform that leverages generative AI to accelerate commercial architecture workflows. | $13M / Seed / May 06, 2026 | ||
| Omneky is an AI-agentic advertising platform that generates and orchestrates personalized omni-channel ad campaigns. By analyzing cross-channel marketing data from platforms like Meta, Google, TikTok, Reddit and LinkedIn, Omneky identifies the specific design elements and messaging that drive conversions. It then leverages generative AI to quicklyproduce and launch highly tailored image and video ads across various advertising channels, helping brands optimize their campaigns, reduce creative fatigue, and ultimately increase return on ad spend. | Venture - Series Unknown / Jan 20, 2026 | ||
| Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | ||
| WearLinq is a provider of wearable health monitoring and diagnosis solutions. The company's device records a multi-lead ECG and transmits it in real-time with AI to detect typical irregular heart rhythms, including a normal heart rhythm, aFib, bradycardia, and tachycardia, allowing users to discover history and trends, set reminders, andconnect directly with physicians. | $14M / Series A / Dec 17, 2025 | ||
| Profluent Bio is an AI-first protein design company that designs novel, optimal proteins that bypass existing barriers in industry. | $106M / Series B / Nov 19, 2025 | ||
| Greenshoe is an AI-powered platform that streamlines SEC disclosure drafting, analysis, and benchmarking for enhanced productivity. | $3M / Seed / Nov 13, 2025 | ||
| Sumble provides a sales intelligence platform that crawls the web for technographic and contact data, giving sales teams context on prospective customers. | $30M / Series A / Oct 22, 2025 | ||
| An artificial intelligence research lab building AI models for creating real-time interactive content | $28M / Seed / Oct 01, 2025 | ||
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does AIX Ventures invest in?
AIX Ventures invests primarily in Artificial Intelligence, Software and Biotechnology startups, most often at Seed and Series A stage. Most of the 62 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AIX Ventures?
Public channels for AIX Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AIX Ventures?
The team at AIX Ventures includes Anthony Goldbloom (Investing Partner), Bianca Caban (Principal) and Christopher Manning (General Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
